Cell MedX Corp.
CMXC · OTC
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $3 | $6 |
| % Growth | – | -100% | -54.5% | – |
| Cost of Goods Sold | $0 | $0 | $2 | $2 |
| Gross Profit | $0 | $0 | $0 | $4 |
| % Margin | – | – | 17.5% | 66.5% |
| R&D Expenses | $64 | $23 | $89 | $151 |
| G&A Expenses | $213 | $291 | $359 | $524 |
| SG&A Expenses | $213 | $291 | $359 | $524 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $245 | $0 | $0 | $1 |
| Operating Expenses | $522 | $313 | $448 | $676 |
| Operating Income | $0 | -$313 | -$448 | -$672 |
| % Margin | – | – | -16,207.7% | -11,074.9% |
| Other Income/Exp. Net | $0 | $171 | -$47 | -$26 |
| Pre-Tax Income | -$566 | -$142 | -$495 | -$697 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$566 | -$142 | -$495 | -$697 |
| % Margin | – | – | -17,923.3% | -11,498.4% |
| EPS | -0.03 | -0.003 | -0.008 | -0.011 |
| % Growth | -782.4% | 57% | 28.8% | – |
| EPS Diluted | -0.03 | -0.003 | -0.008 | -0.011 |
| Weighted Avg Shares Out | 19,843 | 41,370 | 62,923 | 62,799 |
| Weighted Avg Shares Out Dil | 19,843 | 41,370 | 62,923 | 62,799 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $62 | $47 | $26 |
| Depreciation & Amortization | $0 | $268 | $1 | $1 |
| EBITDA | $0 | $0 | -$447 | -$671 |
| % Margin | – | – | -16,166.3% | -11,056% |